M2 TAMs further enhance immune evasion by upregulating PD-L1 and B7-H4, immune checkpoints induced through direct tumor cell contact and correlated with poor prognosis in glioblastoma and hepatocellular carcinoma (54, 55). The gene discussed is VTCN1; the disease is hepatocellular carcinoma.